Key result
Heart failure with preserved ejection fraction currently lacks approved therapies to reduce mortality or hospitalization, highlighting an urgent need for focused drug and device development.
This review highlights the urgent need for drug and device development to address the lack of approved therapies for reducing mortality or hospitalization in HFpEF.
Leaves open urgent unmet need in HFpEF; supports priority for dedicated drug and device trials before practice change.
Heart failure with preserved ejection fraction (HFpEF) portrays a significant burden in terms of prevalence, morbidity, mortality, and health care costs. There is a lack of consensus on the basic pathophysiology, definition, and therapeutic targets for therapy for this syndrome. To date, there are no approved therapies available for reducing mortality or hospitalization for these patients. Several clinical trials have recently started to try and bridge this major gap. There is an urgent need to focus on drug and device development for HFpEF as well as to understand HFpEF pathophysiology.
No takes yet. Share an insight, caveat, or question.
Kanwar et al. (2016) conducted a review in Heart failure with preserved ejection fraction (HFpEF). Heart failure with preserved ejection fraction currently lacks approved therapies to reduce mortality or hospitalization, highlighting an urgent need for focused drug and device development.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: